Delving into the Latest Updates on JW202313 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

JW202313

Target-

Action-

Mechanism-

Therapeutic Areas

Immune System DiseasesRespiratory Diseases

Active Indication

Pulmonary Disease, Chronic ObstructiveAsthma

Inactive Indication-

Originator Organization

Jewim Pharmaceutical (Shandong) Co., Ltd

Active Organization

Jewim Pharmaceutical (Shandong) Co., Ltd

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

[Translation] A comparative pharmacokinetics study of JW202313 inhalation powder, budegol inhalation aerosol (Bexora® Remchang®), budesonide and formoterol inhalation powder (II) (Symbicort Turbo), and indacaterol and glycopyrronium bromide inhalation powder (Jierun®) in healthy Chinese subjects.

主要目的以AstraZeneca AB持证的布地格福吸入气雾剂（倍择瑞®令畅®）、布地奈德福莫特罗吸入粉雾剂（Ⅱ）（信必可都保）及Novartis Pharma Schweiz AG持证的茚达特罗格隆溴铵吸入粉雾剂（杰润®）为对照药品，比较中国健康受试者单次给予JW202313吸入粉雾剂和对照药品后的药物代谢动力学特征。次要目的评价JW202313吸入粉雾剂和布地格福吸入气雾剂（倍择瑞®令畅®）、茚达特罗格隆溴铵吸入粉雾剂（杰润®）及布地奈德福莫特罗吸入粉雾剂（Ⅱ）（信必可都保）的安全性。

[Translation]

Primary Objective To compare the pharmacokinetic profiles of JW202313 inhalation powder in healthy Chinese volunteers after a single dose, using AstraZeneca AB's licensed budegol inhalation aerosol (Bexer® Remchang®), budesonide and formoterol inhalation powder (II) (Symbicort Turbo), and Novartis Pharma Schweiz AG's licensed indacaterol and glycopyrronium inhalation powder (Jierun®) as comparators. Secondary Objective To evaluate the safety of JW202313 inhalation powder in comparison with budegol inhalation aerosol (Bexer® Remchang®), indacaterol and glycopyrronium inhalation powder (Jierun®), and budesonide and formoterol inhalation powder (II) (Symbicort Turbo).

Start Date10 Oct 2025

Sponsor / Collaborator

Jewim Pharmaceutical (Shandong) Co., Ltd

100 Clinical Results associated with JW202313

Login to view more data

100 Translational Medicine associated with JW202313

Login to view more data

100 Patents (Medical) associated with JW202313

Login to view more data

100 Deals associated with JW202313

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	Phase 1	China	Jewim Pharmaceutical (Shandong) Co., Ltd	10 Oct 2025
Asthma	IND Approval	China	Jewim Pharmaceutical (Shandong) Co., Ltd	22 Sep 2025